46 related articles for article (PubMed ID: 27855345)
21. Aldo-keto Reductase 1B10 Restrains Cell Migration, Invasion, and Adhesion of Gastric Cancer via Regulating Integrin Subunit Alpha 5.
Yao H; Hu J; Shao Y; Shah Q; Zheng S
Turk J Gastroenterol; 2023 Dec; 34(12):1197-1205. PubMed ID: 37823316
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of AKR1B1 indicates poor prognosis and promotes gastric cancer progression by regulating the AKT-mTOR pathway.
Liu L; Zhu L; Cheng Z; Sun Y; Zhou Y; Cao J
Aging (Albany NY); 2023 Sep; 15(18):9661-9675. PubMed ID: 37751590
[TBL] [Abstract][Full Text] [Related]
23. A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1.
Zhao H; Dong X; Huang T; Li X
Comput Intell Neurosci; 2022; 2022():9979200. PubMed ID: 35341178
[TBL] [Abstract][Full Text] [Related]
24. The Role of AKR1B10 in Physiology and Pathophysiology.
Endo S; Matsunaga T; Nishinaka T
Metabolites; 2021 May; 11(6):. PubMed ID: 34063865
[TBL] [Abstract][Full Text] [Related]
25. The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.
Ji J; Xu MX; Qian TY; Zhu SZ; Jiang F; Liu ZX; Xu WS; Zhou J; Xiao MB
Mol Biol Rep; 2020 Aug; 47(8):6091-6103. PubMed ID: 32761301
[TBL] [Abstract][Full Text] [Related]
26. Retinoic Acids in the Treatment of Most Lethal Solid Cancers.
Costantini L; Molinari R; Farinon B; Merendino N
J Clin Med; 2020 Jan; 9(2):. PubMed ID: 32012980
[TBL] [Abstract][Full Text] [Related]
27. Selective Inhibition of Human AKR1B10 by
Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
[TBL] [Abstract][Full Text] [Related]
28. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.
Khayami R; Hashemi SR; Kerachian MA
J Cell Mol Med; 2020 Aug; 24(16):8890-8902. PubMed ID: 32633024
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of aldose reductase in human cancer tissues.
Saraswat M; Mrudula T; Kumar PU; Suneetha A; Rao Rao TS; Srinivasulu M; Reddy B
Med Sci Monit; 2006 Dec; 12(12):CR525-529. PubMed ID: 17136009
[TBL] [Abstract][Full Text] [Related]
30. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
31. Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Hevir N; Sinkovec J; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):226-33. PubMed ID: 23146748
[TBL] [Abstract][Full Text] [Related]
32. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
33. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
34. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB
Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
